FORM OF GENERAL RELEASE OF ALL CLAIMSAralez Pharmaceuticals Inc. • March 14th, 2018 • Pharmaceutical preparations
THIS GENERAL RELEASE OF ALL CLAIMS (this “General Release”), dated as of November 30, 2017, is made by and between Scott J. Charles (the “Executive”) and POZEN, Inc. (together with its parent company, Aralez Pharmaceuticals Inc., and their respective successors and assigns, the “Company”).
AMENDMENT NO. 2 TO AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATESCollaboration and License Agreement • March 14th, 2018 • Aralez Pharmaceuticals Inc. • Pharmaceutical preparations
This AMENDMENT NO. 2 TO AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES (the “Amendment”) is made by and between POZEN Inc., a Delaware corporation (“POZEN”), and Horizon Pharma USA, Inc., a Delaware corporation (“Horizon” or “Licensee,” and together with POZEN, the “Parties”). Reference is made to that certain Amended and Restated Collaboration and License Agreement for the United States, dated as of November 18, 2013, by and between POZEN and Horizon, as successor in interest to AstraZeneca AB (“AZ”), as amended (the “Agreement”). All capitalized terms not herein defined shall have the meaning ascribed to them in the Agreement. This Amendment shall be effective as of February 22, 2018.
